MRVI Earnings & Financial Statements
Maravai LifeSciences Holdings, Inc.
$6.62
+$0.08(+1.30%)
48
Overall
60
Value
50
Tech
34
Quality
Market Cap
$1.70B
Volume
1.47M
52W Range
$2.55 - $9.42
Target Price
$7.83
MRVI earnings and financial statements: Maravai LifeSciences Holdings, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MRVI Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $185.74M | $259.19M | $288.94M | $883.00M | $799.24M |
| Cost of revenue | $151.75M | $150.88M | $148.74M | $168.96M | $140.56M |
| Operating income | -$215.27M | -$235.62M | -$31.65M | $574.22M | $554.64M |
| EBITDA | -$145.86M | -$154.02M | $715.34M | $612.78M | $597.25M |
| Net income | -$130.77M | -$144.85M | -$119.03M | $220.21M | $182.04M |
| EPS (diluted) | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $770.58M | $1.01B | $1.49B | $2.28B | $1.92B |
| Total liabilities | $397.87M | $431.04M | $697.57M | $1.38B | $1.37B |
| Shareholders’ equity | $212.38M | $325.29M | $416.75M | $545.22M | $315.50M |
| Cash and equivalents | $216.89M | $322.40M | $574.96M | $632.14M | $551.27M |
| Long-term debt | $316.47M | $321.60M | $550.60M | $522.00M | $524.59M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$57.57M | $7.46M | $126.22M | $535.98M | $368.57M |
| Capital expenditure | -$13.15M | -$29.66M | -$65.55M | -$17.09M | -$14.85M |
| Free cash flow | -$70.72M | -$22.19M | $60.67M | $518.89M | $353.72M |
| Dividends paid | - | $494.0K | $9.61M | $150.21M | $153.45M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MRVI | $6.62 | +1.3% | 1.47M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Maravai LifeSciences Holdings, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW